After asset purchase from Travere, Mirum's Ctexli crosses FDA finish line in rare metabolic disorder
A little less than two years after San Francisco’s Mirum Pharmaceuticals ponied up $210 million to acquire Travere Therapeutics’ bile acid portfolio, the deal has paid off with a fresh FDA approval.
A little less than two years after San Francisco’s Mirum Pharmaceuticals ponied up $210 million to acquire Travere Therapeutics’ bile acid portfolio, the deal has paid off with a fresh FDA approval.
